{"id":11924,"date":"2020-08-04T09:47:00","date_gmt":"2020-08-04T09:47:00","guid":{"rendered":"https:\/\/wordpress2.hdnweb.com\/2020\/08\/04\/janone-changes-internal-drug-candidate-name-from-tv1001sr-to-jan101\/"},"modified":"2020-08-04T09:47:00","modified_gmt":"2020-08-04T09:47:00","slug":"janone-changes-internal-drug-candidate-name-from-tv1001sr-to-jan101","status":"publish","type":"post","link":"https:\/\/wordpress2.hdnweb.com\/en\/2020\/08\/04\/janone-changes-internal-drug-candidate-name-from-tv1001sr-to-jan101\/","title":{"rendered":"JanOne Changes Internal Drug Candidate Name from TV1001SR to JAN101"},"content":{"rendered":"<p><\/p>\n<style type=\"text\/css\"><![CDATA[\n\/* Style Definitions *\/\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n]]><\/style>\n<div class=\"xn-content\">\n<p><span class=\"xn-location\">LAS VEGAS<\/span>, <span class=\"xn-chron\">Aug. 4, 2020<\/span> \/PRNewswire\/ &#8212;\u00a0JanOne Inc. (Nasdaq: JAN), a company focused on bringing treatments to market for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, announces a\u00a0internal name change for its current drug candidate from TV1001SR to JAN101, soon to enter Phase <span class=\"xn-money\">2b<\/span> clinical trials as a potential treatment Peripheral Artery Disease (PAD). The name change will be effective immediately and will be used in all its current and future clinical trials, Indications for a New Drug, clinical and research studies planned to be conducted in the future. <\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n                        <a href=\"https:\/\/mma.prnewswire.com\/media\/973662\/JanOne_With_4C_TM_Logo.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n                    <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/973662\/JanOne_With_4C_TM_Logo.jpg\" title=\"JanOne TM (PRNewsfoto\/JanOne)\" alt=\"JanOne TM (PRNewsfoto\/JanOne)\"\/><\/a>\n                <\/p>\n<\/p><\/div>\n<p>According to JanOne&#8217;s chief executive officer, <span class=\"xn-person\">Tony Isaac<\/span>, &#8220;This internal name change better reflects the new naming convention for all clinical candidates offered in the JanOne pipeline moving forward.&#8221;<\/p>\n<p><b>About JanOne <br \/><\/b>JanOne (NASDAQ: JAN) is focused on bringing medications to market to treat diseases that cause severe pain. By alleviating pain at the source, JanOne aims to reduce the need for opioid prescriptions to treat disease associated pain that can lead to opioid abuse. The company is also exploring solutions for non-addictive pain medications. Its lead candidate JAN101 is for treating peripheral artery disease (PAD), a condition that affects over 8.5 million Americans. JAN101 demonstrated positive results in a Phase 2a clinical trial and Phase <span class=\"xn-money\">2b<\/span> trials are expected to begin in early 2021. JanOne is dedicated to funding resources toward innovation, technology, and education for PAD, associated vascular conditions and neuropathic pain. JanOne continues to operate its legacy businesses under their current brand names, ARCA Recycling and GeoTraq, both of which are undergoing review to determine appropriate strategic alternatives.\u00a0 For more information, visit janone.com <\/p>\n<p>Media contact:<br \/><a target=\"_blank\" href=\"mailto:ir@Janone.com\" rel=\"nofollow\">ir@Janone.com<\/a><br \/>\u00a01\u00a0(800) 400-2247<\/p>\n<p>\u00a0<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2\">\n<\/div>\n<p id=\"PURL\"><img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=LA81641&amp;sd=2020-08-04\"\/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/janone-changes-internal-drug-candidate-name-from-tv1001sr-to-jan101-301105590.html\">http:\/\/www.prnewswire.com\/news-releases\/janone-changes-internal-drug-candidate-name-from-tv1001sr-to-jan101-301105590.html<\/a><\/p>\n<p>SOURCE  JanOne<\/p>\n<\/div>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=LA81641&amp;Transmission_Id=202008040947PR_NEWS_USPR_____LA81641&amp;DateId=20200804\" style=\"border:0px; width:1px; height:1px;\"\/> <\/p>","protected":false},"excerpt":{"rendered":"<div class=\"xn-content\">\n<p><span class=\"xn-location\">LAS VEGAS<\/span>, <span class=\"xn-chron\">Aug. 4, 2020<\/span> \/PRNewswire\/ &#8212;\u00a0JanOne Inc. (Nasdaq: JAN), a company focused on bringing treatments to market for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, announces a\u00a0internal name change for its current drug candidate from TV1001SR to JAN101, soon to enter Phase <span class=\"xn-money\">2b<\/span> clinical trials as a potential treatment Peripheral Artery Disease (PAD). The name change will be effective immediately and will be used in all its&#8230;<\/p>\n","protected":false},"author":1,"featured_media":11925,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[25],"tags":[],"class_list":["post-11924","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-geovanny-vicente"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>JanOne Changes Internal Drug Candidate Name from TV1001SR to JAN101 - Multisitio 2<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/wordpress2.hdnweb.com\/en\/2020\/08\/04\/janone-changes-internal-drug-candidate-name-from-tv1001sr-to-jan101\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"JanOne Changes Internal Drug Candidate Name from TV1001SR to JAN101 - Multisitio 2\" \/>\n<meta property=\"og:description\" content=\"LAS VEGAS, Aug. 4, 2020 \/PRNewswire\/ --\u00a0JanOne Inc. (Nasdaq: JAN), a company focused on bringing treatments to market for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, announces a\u00a0internal name change for its current drug candidate from TV1001SR to JAN101, soon to enter Phase 2b clinical trials as a potential treatment Peripheral Artery Disease (PAD). The name change will be effective immediately and will be used in all its...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/wordpress2.hdnweb.com\/en\/2020\/08\/04\/janone-changes-internal-drug-candidate-name-from-tv1001sr-to-jan101\/\" \/>\n<meta property=\"og:site_name\" content=\"Multisitio 2\" \/>\n<meta property=\"article:published_time\" content=\"2020-08-04T09:47:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/wordpress2.hdnweb.com\/wp-content\/uploads\/2020\/05\/11924_1_95979.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1980\" \/>\n\t<meta property=\"og:image:height\" content=\"456\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"venred\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"venred\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/wordpress2.hdnweb.com\\\/2020\\\/08\\\/04\\\/janone-changes-internal-drug-candidate-name-from-tv1001sr-to-jan101\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/wordpress2.hdnweb.com\\\/2020\\\/08\\\/04\\\/janone-changes-internal-drug-candidate-name-from-tv1001sr-to-jan101\\\/\"},\"author\":{\"name\":\"venred\",\"@id\":\"https:\\\/\\\/wordpress2.hdnweb.com\\\/#\\\/schema\\\/person\\\/c112e8e970f2cfc8553cdb5392b493ad\"},\"headline\":\"JanOne Changes Internal Drug Candidate Name from TV1001SR to JAN101\",\"datePublished\":\"2020-08-04T09:47:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/wordpress2.hdnweb.com\\\/2020\\\/08\\\/04\\\/janone-changes-internal-drug-candidate-name-from-tv1001sr-to-jan101\\\/\"},\"wordCount\":303,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/wordpress2.hdnweb.com\\\/2020\\\/08\\\/04\\\/janone-changes-internal-drug-candidate-name-from-tv1001sr-to-jan101\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/wordpress2.hdnweb.com\\\/wp-content\\\/uploads\\\/2020\\\/05\\\/11924_1_95979.jpg\",\"articleSection\":[\"Geovanny Vicente\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/wordpress2.hdnweb.com\\\/en\\\/2020\\\/08\\\/04\\\/janone-changes-internal-drug-candidate-name-from-tv1001sr-to-jan101\\\/\",\"url\":\"https:\\\/\\\/wordpress2.hdnweb.com\\\/en\\\/2020\\\/08\\\/04\\\/janone-changes-internal-drug-candidate-name-from-tv1001sr-to-jan101\\\/\",\"name\":\"JanOne Changes Internal Drug Candidate Name from TV1001SR to JAN101 - Multisitio 2\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/wordpress2.hdnweb.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/wordpress2.hdnweb.com\\\/en\\\/2020\\\/08\\\/04\\\/janone-changes-internal-drug-candidate-name-from-tv1001sr-to-jan101\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/wordpress2.hdnweb.com\\\/2020\\\/08\\\/04\\\/janone-changes-internal-drug-candidate-name-from-tv1001sr-to-jan101\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/wordpress2.hdnweb.com\\\/wp-content\\\/uploads\\\/2020\\\/05\\\/11924_1_95979.jpg\",\"datePublished\":\"2020-08-04T09:47:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/wordpress2.hdnweb.com\\\/#\\\/schema\\\/person\\\/c112e8e970f2cfc8553cdb5392b493ad\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/wordpress2.hdnweb.com\\\/en\\\/2020\\\/08\\\/04\\\/janone-changes-internal-drug-candidate-name-from-tv1001sr-to-jan101\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[[\"https:\\\/\\\/wordpress2.hdnweb.com\\\/en\\\/2020\\\/08\\\/04\\\/janone-changes-internal-drug-candidate-name-from-tv1001sr-to-jan101\\\/\"]]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/wordpress2.hdnweb.com\\\/en\\\/2020\\\/08\\\/04\\\/janone-changes-internal-drug-candidate-name-from-tv1001sr-to-jan101\\\/#primaryimage\",\"url\":\"https:\\\/\\\/wordpress2.hdnweb.com\\\/wp-content\\\/uploads\\\/2020\\\/05\\\/11924_1_95979.jpg\",\"contentUrl\":\"https:\\\/\\\/wordpress2.hdnweb.com\\\/wp-content\\\/uploads\\\/2020\\\/05\\\/11924_1_95979.jpg\",\"width\":1980,\"height\":456,\"caption\":\"JanOne TM (PRNewsfoto\\\/JanOne)\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/wordpress2.hdnweb.com\\\/en\\\/2020\\\/08\\\/04\\\/janone-changes-internal-drug-candidate-name-from-tv1001sr-to-jan101\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/wordpress2.hdnweb.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"JanOne Changes Internal Drug Candidate Name from TV1001SR to JAN101\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/wordpress2.hdnweb.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/wordpress2.hdnweb.com\\\/en\\\/\",\"name\":\"Multisitio 2\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/wordpress2.hdnweb.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/wordpress2.hdnweb.com\\\/#\\\/schema\\\/person\\\/c112e8e970f2cfc8553cdb5392b493ad\",\"name\":\"venred\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2b023a883433f83ad0a3036a7ba60d3133c4e0619f3bca6230ba8c7521b6dec8?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2b023a883433f83ad0a3036a7ba60d3133c4e0619f3bca6230ba8c7521b6dec8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2b023a883433f83ad0a3036a7ba60d3133c4e0619f3bca6230ba8c7521b6dec8?s=96&d=mm&r=g\",\"caption\":\"venred\"},\"url\":\"https:\\\/\\\/wordpress2.hdnweb.com\\\/en\\\/author\\\/venred\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"JanOne Changes Internal Drug Candidate Name from TV1001SR to JAN101 - Multisitio 2","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/wordpress2.hdnweb.com\/en\/2020\/08\/04\/janone-changes-internal-drug-candidate-name-from-tv1001sr-to-jan101\/","og_locale":"en_US","og_type":"article","og_title":"JanOne Changes Internal Drug Candidate Name from TV1001SR to JAN101 - Multisitio 2","og_description":"LAS VEGAS, Aug. 4, 2020 \/PRNewswire\/ --\u00a0JanOne Inc. (Nasdaq: JAN), a company focused on bringing treatments to market for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, announces a\u00a0internal name change for its current drug candidate from TV1001SR to JAN101, soon to enter Phase 2b clinical trials as a potential treatment Peripheral Artery Disease (PAD). The name change will be effective immediately and will be used in all its...","og_url":"https:\/\/wordpress2.hdnweb.com\/en\/2020\/08\/04\/janone-changes-internal-drug-candidate-name-from-tv1001sr-to-jan101\/","og_site_name":"Multisitio 2","article_published_time":"2020-08-04T09:47:00+00:00","og_image":[{"width":1980,"height":456,"url":"https:\/\/wordpress2.hdnweb.com\/wp-content\/uploads\/2020\/05\/11924_1_95979.jpg","type":"image\/jpeg"}],"author":"venred","twitter_card":"summary_large_image","twitter_misc":{"Written by":"venred","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/wordpress2.hdnweb.com\/2020\/08\/04\/janone-changes-internal-drug-candidate-name-from-tv1001sr-to-jan101\/#article","isPartOf":{"@id":"https:\/\/wordpress2.hdnweb.com\/2020\/08\/04\/janone-changes-internal-drug-candidate-name-from-tv1001sr-to-jan101\/"},"author":{"name":"venred","@id":"https:\/\/wordpress2.hdnweb.com\/#\/schema\/person\/c112e8e970f2cfc8553cdb5392b493ad"},"headline":"JanOne Changes Internal Drug Candidate Name from TV1001SR to JAN101","datePublished":"2020-08-04T09:47:00+00:00","mainEntityOfPage":{"@id":"https:\/\/wordpress2.hdnweb.com\/2020\/08\/04\/janone-changes-internal-drug-candidate-name-from-tv1001sr-to-jan101\/"},"wordCount":303,"commentCount":0,"image":{"@id":"https:\/\/wordpress2.hdnweb.com\/2020\/08\/04\/janone-changes-internal-drug-candidate-name-from-tv1001sr-to-jan101\/#primaryimage"},"thumbnailUrl":"https:\/\/wordpress2.hdnweb.com\/wp-content\/uploads\/2020\/05\/11924_1_95979.jpg","articleSection":["Geovanny Vicente"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/wordpress2.hdnweb.com\/en\/2020\/08\/04\/janone-changes-internal-drug-candidate-name-from-tv1001sr-to-jan101\/","url":"https:\/\/wordpress2.hdnweb.com\/en\/2020\/08\/04\/janone-changes-internal-drug-candidate-name-from-tv1001sr-to-jan101\/","name":"JanOne Changes Internal Drug Candidate Name from TV1001SR to JAN101 - Multisitio 2","isPartOf":{"@id":"https:\/\/wordpress2.hdnweb.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/wordpress2.hdnweb.com\/en\/2020\/08\/04\/janone-changes-internal-drug-candidate-name-from-tv1001sr-to-jan101\/#primaryimage"},"image":{"@id":"https:\/\/wordpress2.hdnweb.com\/2020\/08\/04\/janone-changes-internal-drug-candidate-name-from-tv1001sr-to-jan101\/#primaryimage"},"thumbnailUrl":"https:\/\/wordpress2.hdnweb.com\/wp-content\/uploads\/2020\/05\/11924_1_95979.jpg","datePublished":"2020-08-04T09:47:00+00:00","author":{"@id":"https:\/\/wordpress2.hdnweb.com\/#\/schema\/person\/c112e8e970f2cfc8553cdb5392b493ad"},"breadcrumb":{"@id":"https:\/\/wordpress2.hdnweb.com\/en\/2020\/08\/04\/janone-changes-internal-drug-candidate-name-from-tv1001sr-to-jan101\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":[["https:\/\/wordpress2.hdnweb.com\/en\/2020\/08\/04\/janone-changes-internal-drug-candidate-name-from-tv1001sr-to-jan101\/"]]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/wordpress2.hdnweb.com\/en\/2020\/08\/04\/janone-changes-internal-drug-candidate-name-from-tv1001sr-to-jan101\/#primaryimage","url":"https:\/\/wordpress2.hdnweb.com\/wp-content\/uploads\/2020\/05\/11924_1_95979.jpg","contentUrl":"https:\/\/wordpress2.hdnweb.com\/wp-content\/uploads\/2020\/05\/11924_1_95979.jpg","width":1980,"height":456,"caption":"JanOne TM (PRNewsfoto\/JanOne)"},{"@type":"BreadcrumbList","@id":"https:\/\/wordpress2.hdnweb.com\/en\/2020\/08\/04\/janone-changes-internal-drug-candidate-name-from-tv1001sr-to-jan101\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/wordpress2.hdnweb.com\/en\/"},{"@type":"ListItem","position":2,"name":"JanOne Changes Internal Drug Candidate Name from TV1001SR to JAN101"}]},{"@type":"WebSite","@id":"https:\/\/wordpress2.hdnweb.com\/en\/#website","url":"https:\/\/wordpress2.hdnweb.com\/en\/","name":"Multisitio 2","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/wordpress2.hdnweb.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/wordpress2.hdnweb.com\/#\/schema\/person\/c112e8e970f2cfc8553cdb5392b493ad","name":"venred","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/2b023a883433f83ad0a3036a7ba60d3133c4e0619f3bca6230ba8c7521b6dec8?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/2b023a883433f83ad0a3036a7ba60d3133c4e0619f3bca6230ba8c7521b6dec8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2b023a883433f83ad0a3036a7ba60d3133c4e0619f3bca6230ba8c7521b6dec8?s=96&d=mm&r=g","caption":"venred"},"url":"https:\/\/wordpress2.hdnweb.com\/en\/author\/venred\/"}]}},"_links":{"self":[{"href":"https:\/\/wordpress2.hdnweb.com\/en\/wp-json\/wp\/v2\/posts\/11924","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wordpress2.hdnweb.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wordpress2.hdnweb.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/wordpress2.hdnweb.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/wordpress2.hdnweb.com\/en\/wp-json\/wp\/v2\/comments?post=11924"}],"version-history":[{"count":0,"href":"https:\/\/wordpress2.hdnweb.com\/en\/wp-json\/wp\/v2\/posts\/11924\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/wordpress2.hdnweb.com\/en\/wp-json\/wp\/v2\/media\/11925"}],"wp:attachment":[{"href":"https:\/\/wordpress2.hdnweb.com\/en\/wp-json\/wp\/v2\/media?parent=11924"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wordpress2.hdnweb.com\/en\/wp-json\/wp\/v2\/categories?post=11924"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wordpress2.hdnweb.com\/en\/wp-json\/wp\/v2\/tags?post=11924"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}